US and China should collaborate more to bring AI to healthcare
New article says that to take full advantage of deep-learning solutions in healthcare, the US and China should collaborate, not compete.
List view / Grid view
New article says that to take full advantage of deep-learning solutions in healthcare, the US and China should collaborate, not compete.
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
The rise of manufacturing advanced drugs will stimulate growth in the pharmaceutical chemical market.
The US supply of heparin, an ingredient used in anticoagulant drugs and found in pigs, is under threat due to an outbreak of disease in Chinese herds.
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
A fund of almost £450 million has been announced by the UK Government to mitigate drug shortages in the event of a no-deal Brexit.
Tecan Partnering has consolidated its extensive OEM system development services for life sciences and IVD instruments to create Tecan Synergence™.
A three-drug combination injection to treat patients with complicated urinary tract and intra-abdominal infections has been approved by the FDA.
The two Canadian provinces have expressed concern over the new draft regulations, claiming that the reforms would delay patient access to medicines.
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
According to a new report, pharma companies in India are increasingly entering the Chinese pharma industry through joint ventures.
The Middle Eastern country has a limited supply of vital medication needed for conditions such as cancer due to US trade blocks.
FDA approves Nubeqa (darolutamide) as a new treatment for men with non-metastatic castration-resistant prostate cancer.
The global pharmaceutical robots market is set to be worth $344.4m at the end of a forecast period, after seeing substantial growth.
A new study undertaken to better understand the economic impact of brand-brand competition finds this does not lower drug prices.